Study on the improvement of behavior and pain and the mechanism of Yangpafang in subacute Parkinson's disease model mice

Objective Explore the therapeutic effect of Yangpafang on behavior and pain in subacute Parkinson's disease (PD) model mice and its possible mechanism. Methods Total 42 specific pathogen⁃free (SPF) C57BL/6J mice were randomly divided into control group, model group, Yangpafang low⁃ dose group [...

Full description

Saved in:
Bibliographic Details
Main Authors: SHI Ying, MEI Shan‐shan, WANG Yuan‐ling, XIA A‐long, WANG Xiao‐wei, LI Jun
Format: Article
Language:English
Published: Tianjin Huanhu Hospital 2024-12-01
Series:Chinese Journal of Contemporary Neurology and Neurosurgery
Subjects:
Online Access:http://www.cjcnn.org/index.php/cjcnn/article/view/2970
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841536624095133696
author SHI Ying
MEI Shan‐shan
WANG Yuan‐ling
XIA A‐long
WANG Xiao‐wei
LI Jun
author_facet SHI Ying
MEI Shan‐shan
WANG Yuan‐ling
XIA A‐long
WANG Xiao‐wei
LI Jun
author_sort SHI Ying
collection DOAJ
description Objective Explore the therapeutic effect of Yangpafang on behavior and pain in subacute Parkinson's disease (PD) model mice and its possible mechanism. Methods Total 42 specific pathogen⁃free (SPF) C57BL/6J mice were randomly divided into control group, model group, Yangpafang low⁃ dose group [13.50 g/(kg·d)], medium ⁃dose group [40.50 g/(kg·d)] and high⁃dose group [121.50 g/(kg·d)], levodopa and benserazide group (7 mice in each group). The behavioral changes of mice were evaluated by Pole Climbing Test, Suspension Test and Field Test. The thermal nociceptive threshold and mechanical nociceptive threshold were measured by thermal pain response latency measuring instrument and electronic pressure pain measuring instrument. Immunohistochemical staining was used to detect the positive expression of tyrosine hydroxylase (TH) in substantia nigra and amygdala. Results There were significant differences in pole climbing time (F = 14.625, P = 0.000), suspension score (F = 24.493, P = 0.000), resting time of Field Test (F = 24.506, P = 0.000), thermal nociceptive threshold (F = 24.726, P = 0.000) and mechanical nociceptive threshold (F = 21.052, P = 0.000), TH positive expression in substantia nigra (F = 19.663, P = 0.000) and amygdala (F = 36.513, P = 0.000) among different treatment groups. Compared with the control group, the pole climbing time (P = 0.000) and resting time (P = 0.000) of the model group were prolonged, and the suspension score (P = 0.000), thermal nociceptive threshold (P = 0.000) and mechanical nociceptive threshold (P = 0.000), substantia nigra (P = 0.000) and amygdala (P = 0.000) TH positive expression decreased. Compared with the model group, the pole climbing time (P = 0.020, 0.000, 0.000, 0.000) and resting time (P = 0.000, 0.000, 0.000, 0.000) of Yangpafang low⁃dose group, medium⁃dose group, high ⁃ dose group and levodopa and benserazide group were shortened, but still longer than those of the control group (P < 0.05, for all). The suspension score (P = 0.000, 0.000, 0.000, 0.000, 0.000), thermal nociceptive threshold (P = 0.008, 0.000, 0.000, 0.000) and mechanical nociceptive threshold (P = 0.003, 0.000, 0.000, 0.000), TH positive expression in substantia nigra (P = 0.031, 0.001, 0.000, 0.000) and amygdala (P = 0.007, 0.000, 0.000, 0.000) increased. The thermal nociceptive threshold in other 3 groups was still lower than that in the control group (P < 0.05, for all), except that the levodopa and benserazide group returned to the level of the control group (P = 0.063). Compared with the Yangpafang low⁃dose group, the pole climbing time (P = 0.009, 0.009, 0.006) and resting time (P = 0.024, 0.018, 0.001) in the Yangpafang medium ⁃ dose group, high ⁃ dose group and the levodopa and benserazide group were also shortened, but still longer than those in the control group (P < 0.05, for all). Suspension score (P = 0.015, 0.011, 0.002), thermal nociceptive threshold (P = 0.001, 0.001, 0.000) and mechanical nociceptive threshold (P = 0.035, 0.001, 0.001) also increased, TH positive expression was also increased in the substantia nigra (P = 0.043, 0.023, 0.001) and amygdala (P = 0.007, 0.005, 0.000). Except that the TH positive expression in the amygdala of the levodopa and benserazide group was higher than that of the Yangpafang medium⁃dose group (P = 0.009) and the high⁃dose group (P = 0.012), there was no significant difference in each index between the latter 3 groups (P > 0.05, for all). Conclusions Yangpafang can improve the behavior and pain of subacute PD model mice, which is related to the protection of amygdala and substantia nigra dopaminergic neurons.
format Article
id doaj-art-20fe8d38c43f4270b193fe48e22366cd
institution Kabale University
issn 1672-6731
language English
publishDate 2024-12-01
publisher Tianjin Huanhu Hospital
record_format Article
series Chinese Journal of Contemporary Neurology and Neurosurgery
spelling doaj-art-20fe8d38c43f4270b193fe48e22366cd2025-01-14T12:30:24ZengTianjin Huanhu HospitalChinese Journal of Contemporary Neurology and Neurosurgery1672-67312024-12-0124121036104610.3969/j.issn.1672⁃6731.2024.12.011Study on the improvement of behavior and pain and the mechanism of Yangpafang in subacute Parkinson's disease model miceSHI Ying0MEI Shan‐shan1WANG Yuan‐ling2XIA A‐long3WANG Xiao‐wei4LI Jun5Grade 2022, The First Clinical Medical College of Anhui University of Chinese Medicine, Hefei 230031, Anhui, ChinaDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, ChinaGrade 2022, The First Clinical Medical College of Anhui University of Chinese Medicine, Hefei 230031, Anhui, ChinaGrade 2022, The First Clinical Medical College of Anhui University of Chinese Medicine, Hefei 230031, Anhui, ChinaGrade 2022, The First Clinical Medical College of Anhui University of Chinese Medicine, Hefei 230031, Anhui, ChinaDepartment of Neurology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, Anhui, ChinaObjective Explore the therapeutic effect of Yangpafang on behavior and pain in subacute Parkinson's disease (PD) model mice and its possible mechanism. Methods Total 42 specific pathogen⁃free (SPF) C57BL/6J mice were randomly divided into control group, model group, Yangpafang low⁃ dose group [13.50 g/(kg·d)], medium ⁃dose group [40.50 g/(kg·d)] and high⁃dose group [121.50 g/(kg·d)], levodopa and benserazide group (7 mice in each group). The behavioral changes of mice were evaluated by Pole Climbing Test, Suspension Test and Field Test. The thermal nociceptive threshold and mechanical nociceptive threshold were measured by thermal pain response latency measuring instrument and electronic pressure pain measuring instrument. Immunohistochemical staining was used to detect the positive expression of tyrosine hydroxylase (TH) in substantia nigra and amygdala. Results There were significant differences in pole climbing time (F = 14.625, P = 0.000), suspension score (F = 24.493, P = 0.000), resting time of Field Test (F = 24.506, P = 0.000), thermal nociceptive threshold (F = 24.726, P = 0.000) and mechanical nociceptive threshold (F = 21.052, P = 0.000), TH positive expression in substantia nigra (F = 19.663, P = 0.000) and amygdala (F = 36.513, P = 0.000) among different treatment groups. Compared with the control group, the pole climbing time (P = 0.000) and resting time (P = 0.000) of the model group were prolonged, and the suspension score (P = 0.000), thermal nociceptive threshold (P = 0.000) and mechanical nociceptive threshold (P = 0.000), substantia nigra (P = 0.000) and amygdala (P = 0.000) TH positive expression decreased. Compared with the model group, the pole climbing time (P = 0.020, 0.000, 0.000, 0.000) and resting time (P = 0.000, 0.000, 0.000, 0.000) of Yangpafang low⁃dose group, medium⁃dose group, high ⁃ dose group and levodopa and benserazide group were shortened, but still longer than those of the control group (P < 0.05, for all). The suspension score (P = 0.000, 0.000, 0.000, 0.000, 0.000), thermal nociceptive threshold (P = 0.008, 0.000, 0.000, 0.000) and mechanical nociceptive threshold (P = 0.003, 0.000, 0.000, 0.000), TH positive expression in substantia nigra (P = 0.031, 0.001, 0.000, 0.000) and amygdala (P = 0.007, 0.000, 0.000, 0.000) increased. The thermal nociceptive threshold in other 3 groups was still lower than that in the control group (P < 0.05, for all), except that the levodopa and benserazide group returned to the level of the control group (P = 0.063). Compared with the Yangpafang low⁃dose group, the pole climbing time (P = 0.009, 0.009, 0.006) and resting time (P = 0.024, 0.018, 0.001) in the Yangpafang medium ⁃ dose group, high ⁃ dose group and the levodopa and benserazide group were also shortened, but still longer than those in the control group (P < 0.05, for all). Suspension score (P = 0.015, 0.011, 0.002), thermal nociceptive threshold (P = 0.001, 0.001, 0.000) and mechanical nociceptive threshold (P = 0.035, 0.001, 0.001) also increased, TH positive expression was also increased in the substantia nigra (P = 0.043, 0.023, 0.001) and amygdala (P = 0.007, 0.005, 0.000). Except that the TH positive expression in the amygdala of the levodopa and benserazide group was higher than that of the Yangpafang medium⁃dose group (P = 0.009) and the high⁃dose group (P = 0.012), there was no significant difference in each index between the latter 3 groups (P > 0.05, for all). Conclusions Yangpafang can improve the behavior and pain of subacute PD model mice, which is related to the protection of amygdala and substantia nigra dopaminergic neurons.http://www.cjcnn.org/index.php/cjcnn/article/view/2970parkinson diseasebehavior and behavior mechanismspainsensory thresholdstyrosine 3‐monooxygenaseimmunohistochemistrydisease models,animal
spellingShingle SHI Ying
MEI Shan‐shan
WANG Yuan‐ling
XIA A‐long
WANG Xiao‐wei
LI Jun
Study on the improvement of behavior and pain and the mechanism of Yangpafang in subacute Parkinson's disease model mice
Chinese Journal of Contemporary Neurology and Neurosurgery
parkinson disease
behavior and behavior mechanisms
pain
sensory thresholds
tyrosine 3‐monooxygenase
immunohistochemistry
disease models,animal
title Study on the improvement of behavior and pain and the mechanism of Yangpafang in subacute Parkinson's disease model mice
title_full Study on the improvement of behavior and pain and the mechanism of Yangpafang in subacute Parkinson's disease model mice
title_fullStr Study on the improvement of behavior and pain and the mechanism of Yangpafang in subacute Parkinson's disease model mice
title_full_unstemmed Study on the improvement of behavior and pain and the mechanism of Yangpafang in subacute Parkinson's disease model mice
title_short Study on the improvement of behavior and pain and the mechanism of Yangpafang in subacute Parkinson's disease model mice
title_sort study on the improvement of behavior and pain and the mechanism of yangpafang in subacute parkinson s disease model mice
topic parkinson disease
behavior and behavior mechanisms
pain
sensory thresholds
tyrosine 3‐monooxygenase
immunohistochemistry
disease models,animal
url http://www.cjcnn.org/index.php/cjcnn/article/view/2970
work_keys_str_mv AT shiying studyontheimprovementofbehaviorandpainandthemechanismofyangpafanginsubacuteparkinsonsdiseasemodelmice
AT meishanshan studyontheimprovementofbehaviorandpainandthemechanismofyangpafanginsubacuteparkinsonsdiseasemodelmice
AT wangyuanling studyontheimprovementofbehaviorandpainandthemechanismofyangpafanginsubacuteparkinsonsdiseasemodelmice
AT xiaalong studyontheimprovementofbehaviorandpainandthemechanismofyangpafanginsubacuteparkinsonsdiseasemodelmice
AT wangxiaowei studyontheimprovementofbehaviorandpainandthemechanismofyangpafanginsubacuteparkinsonsdiseasemodelmice
AT lijun studyontheimprovementofbehaviorandpainandthemechanismofyangpafanginsubacuteparkinsonsdiseasemodelmice